Click to go to DrugInjuryLaw Home


Legal information and news about prescription drug side effects
NuvaRing Case Evaluation Ortho Evra Case Evaluation Fosamax Case Evaluation Avandia Case EvaluationKetek Case Evaluation Zelnorm Case Evaluation Meridia Case Evaluation Zocor Case Evaluation
Vytorin Case EvaluationZetia Case Evaluation Yasmin Case Evaluation Ocella Case EvaluationYAZ Case Evaluation Levaquin Case Evaluation Byetta Case Evaluation Gianvi Case Evaluation


Free Case Evaluation

Natrecor Information

What is Natrecor?

Natrecor® is the name under which Scios, a Johnson & Johnson company, markets a prescription medication for patients with acutely decompensated congestive heart failure, generically called nesiritide. Natrecor also targets the dyspnea, or shortness of breath, which can accompany heart failure.

Should Heart Failure Drug Natrecor Be Recalled Due to Safety Questions?
A July 14, 2005 article by renowned cardiologist Eric J. Topol in the The New England Journal of Medicine prompted letters to the editor supporting and disputing Dr. Topol's concerns. The letters were published, along with Dr. Topol's reply, in the NEJM's October 6, 2005 edition.


Natrecor Maker Scios Gets Subpoena: Boston US Attorney's Office Requesting Documents Related to the Sales and Marketing of Natrecor
Johnson & Johnson's aggressive marketing of its heart-failure treatment Natrecor has become the subject of an inquiry by the Justice Department. Johnson & Johnson subsidiary Scios received a subpoena from Michael Sullivan of the U.S. Attorney's Office in Massachusetts on July 21, 2005 over its marketing of Natrecor. The subpoena followed allegations from some doctors that Scios has been promoting off-label uses of the drug.


Natrecor Dear Doctor Letters May 2005 and July 2005
On May 6, 2005, Scios and the FDA notified health care professionals of revisions to the Adverse Reactions/Effect on Mortality section of the prescribing information for Natrecor in an April Dear Doctor letter, and on July 13, 2005, a second Dear Doctor letter was issued to advise health care professionals that the use of Natrecor should be strictly limited to patients presenting to the hospital with acutely decompensated congestive heart failure who have dyspnea at rest.


Natrecor Class Actions
Our law firm believes that people injured by Natrecor are better served by having an individual lawsuit filed instead of joining a class action lawsuit.


Natrecor and Legal Compensation
How to get legal compensation for a Natrecor injury or death.




Natrecor Case Evaluation
The information you provide to us for this Free Case Evaluation will be treated as strictly confidential.  You will get a reply from us no later than the next business day.  Submitting a case evaluation does not obligate you to hire our law firm for your lawsuit.  We handle all cases on a contingency fee basis, which means that you will make no payment for our legal services until after we have succeeded in getting legal compensation for you.

Drug Injury Watch: Natrecor News Commentary


  • US FDA advises that you should not stop taking any prescription medication before talking to your doctor.
  • Reports of serious drug side effects should be made to the US FDA MedWatch program.
  • The prescription drug names are registered trademarks of the respective drug companies.
  • DrugInjuryLaw.com is not affiliated with any of the drug companies, nor US FDA.
Law Offices of Thomas J. Lamb, P.A.
Lumina Station Suite 225
1908 Eastwood Road
Wilmington, NC 28403
Tel: (910) 256-2971   Fax: (910) 256-2972
Toll Free: (800) 426-9535
email: ThomasJLamb@DrugInjuryLaw.com

Disclaimer